Accendra Health: receives NYSE notice for sub-$1.00 share price

What happened

• The company received a notice from the New York Stock Exchange on Oct 6, 2026 stating it was not in compliance with Section 802.01C because the average closing price of the company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period.
• The notice has no immediate impact on the listing of the common stock on the NYSE, subject to the company’s compliance with the NYSE’s other continued listing requirements.
• The company said it intends to notify the NYSE within 10 business days of receipt of the notice of its intent to cure the deficiency and will consider alternatives to regain compliance. On Oct 9, 2026 the company issued a press release related to the notice, furnished as Exhibit 99.1 to the Form 8-K.

Key details

• Date notice received: Oct 6, 2026.
• Relevant rule: Section 802.01C of the NYSE Listed Company Manual; deficiency relates to average closing price below $1.00 over a consecutive 30 trading-day period.
• Cure period: 6 months from receipt of the notice; company may regain compliance if, on the last trading day of any calendar month during the 6-month period or on the last day of the cure period, the closing price and 30 trading-day average are at least $1.00 per share.
• Regulation FD disclosure: press release dated Oct 9, 2026 furnished as Exhibit 99.1.

Why it may matter

• Reported items: Item 3.01 (notice of delisting or failure to satisfy a continued listing standard) and Item 7.01 (Regulation FD disclosure). Item 3.01 covers the NYSE notice about the minimum share price requirement; Item 7.01 covers the related press release.
• This filing does not show why the insider traded or why the company acted.